© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 4, 300-308,
February 21, 2001
© 2001 Oxford University Press
Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study
Affiliations of authors: J.-L. Pujol, X. Quantin, Centre Hôpital Universitaire Arnaud de Villeneuve, Montpellier, France; J.-P. Daurès, Institut Universitaire de la Recherche Clinique, Montpellier; A. Rivière, Centre Régional de Lutte contre le Cancer, François Baclesse, Caen, France; E. Quoix, Hôpital Universitaire de Strasbourg, France; V. Westeel, Hôpital Universitaire de Besançon, France; J.-L. Breton, Hôpital de Belfort, France; E. Lemarié, Hôpital Universitaire de Tours, France; M. Poudenx, Centre Régional de Lutte contre le Cancer, Antoine Lacassagne, Nice, France; B. Milleron, Hôpital Universitaire Tenon, Paris, France; D. Moro, Hôpital Universitaire de Grenoble, France; D. Diebieuvre, Hôpital de Vesoul, France; T. Le Chevalier, Institut Gustave Roussy, Villejuif, France.
Correspondence to: Jean-Louis Pujol, M.D., Hôpital Universitaire Arnaud de Villeneuve, 34295 Montpellier, Cedex 5 France (e-mail: pujol{at}cyber-sante.org).
Background: The combination of etoposide plus cisplatin (EP) is considered to be standard therapy for small-cell lung cancer (SCLC). To determine whether drug intensification improves survival of patients with extensive SCLC, we compared this treatment with a four-drug regimen containing EP plus cyclophosphamide and 4'-epidoxorubicin (PCDE). Methods: In a phase III clinical trial organized by the French Federation of Cancer Institutes, patients were randomly assigned to receive either EP (n = 109; etoposide at a dose of 100 mg/m2 on days 1–3 plus cisplatin at 100 mg/m2 on day 2) or PCDE (n = 117; etoposide and cisplatin given as in EP plus cyclophosphamide at 400 mg/m2 on days 1–3 and 4'-epidoxorubicin at 40 mg/m2 on day 1) every 4 weeks. Both groups received a total of six cycles. Survival differences were analyzed by Wilcoxon and log-rank tests. Associations of treatment group and putative prognostic variables with survival were tested in the Cox proportional hazards model. Quality of life was assessed from the responses to the European Organization for Research and Treatment of Cancer quality-of-life questionnaire (C30, health status and lung cancer module 13). All statistical tests were two-sided. Results: Patients in the PCDE arm had a statistically significant higher frequency of combined complete plus partial responses compared with those in the EP arm (21% plus 55% versus 13% plus 48%, respectively; P = .02 for difference in combined objective responses). Patients in the PCDE arm survived longer than those in the EP arm (1-year survival rate: 40% and 29%, respectively; median survival: 10.5 and 9.3 months, respectively; log-rank P = .0067). In the Cox model, the relative risk of death for patients in the PCDE arm compared with those in the EP arm was 0.70 (95% confidence interval = 0.51 to 0.95); the disease also progressed more slowly in patients in the PCDE arm. Hematologic toxicity was higher in the PCDE arm (22% with documented infections compared with 8% in the EP arm; P = .0038), and the toxicity-related death rate was 9% in the PCDE arm versus 5.5% in the EP arm (P = .22). The global health status showed similar improvement in both arms during treatment. Conclusion: Compared with the EP regimen, the PCDE regimen yielded higher response rates and better survival rates in patients with extensive SCLC without affecting the quality of life of the patients during chemotherapy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Leyvraz, S. Pampallona, G. Martinelli, F. Ploner, L. Perey, S. Aversa, S. Peters, P. Brunsvig, A. Montes, A. Lange, et al. A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial J Natl Cancer Inst, April 16, 2008; 100(8): 533 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Pujol In Reply: J. Clin. Oncol., January 1, 2008; 26(1): 160 - 161. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pautier, V. Ribrag, P. Duvillard, A. Rey, I. Elghissassi, I. Sillet-Bach, P. Kerbrat, F. Mayer, A. Lesoin, B. Brun, et al. Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type Ann. Onc., December 1, 2007; 18(12): 1985 - 1989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Pujol, J. L. Breton, R. Gervais, M.-L. Tanguy, E. Quoix, P. David, H. Janicot, V. Westeel, S. Gameroff, J. Geneve, et al. Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04 IFCT 00-01 J. Clin. Oncol., September 1, 2007; 25(25): 3945 - 3951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Lally, J. J. Urbanic, A. W. Blackstock, A. A. Miller, and M. C. Perry Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years? Oncologist, September 1, 2007; 12(9): 1096 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Hainsworth, D. R. Spigel, S. Litchy, and F. A. Greco Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study J. Clin. Oncol., August 1, 2006; 24(22): 3548 - 3554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Thatcher, W. Qian, P. I. Clark, P. Hopwood, R. J. Sambrook, R. Owens, R. J. Stephens, and D. J. Girling Ifosfamide, Carboplatin, and Etoposide With Midcycle Vincristine Versus Standard Chemotherapy in Patients With Small-Cell Lung Cancer and Good Performance Status: Clinical and Quality-of-Life Results of the British Medical Research Council Multicenter Randomized LU21 Trial J. Clin. Oncol., November 20, 2005; 23(33): 8371 - 8379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Gralla Quality-of-Life Considerations in Patients with Advanced Lung Cancer: Effect of Topotecan on Symptom Palliation and Quality of Life Oncologist, December 1, 2004; 9(suppl_6): 14 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Booton, M Jones, and N Thatcher Lung cancer * 7: Management of lung cancer in elderly patients Thorax, August 1, 2003; 58(8): 711 - 720. [Full Text] [PDF]
|
|
|
|
|
|
W. West, R. Birch, F. Schnell, J. Hainsworth, J. Tongol, and L. Campos Phase I Study of Paclitaxel and Topotecan for the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer Oncologist, February 1, 2003; 8(1): 76 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Johnson Is More Better? Chemotherapy for Patients With Extensive-Stage Small-Cell Lung Cancer J Natl Cancer Inst, February 21, 2001; 93(4): 254 - 255. [Full Text] [PDF]
|
|